At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 1,899 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 7
- ✓Diagnosis of IPAH, HPAH, or APAH
- ✓Family members of affected persons
- ✓Project 1: Age 0-90 (age 12-90 for skin biopsy)
- ✓Project 2: Age 0-90
Key exclusion· 5
- ✕Other diagnosis (not IPAH, HPAH, or APAH)
- ✕Project 1: Age greater than 90; age less than 12 or greater than 90 for skin biopsy
- ✕Project 2: Difficulty reaching clinic for blood collection and testing
- ✕Project 2: Unable to tolerate fasting state
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
In Brief
An observational study for Idiopathic Pulmonary Arterial Hypertension and 3 related conditions. Currently recruiting, targeting 1,899 participants across 1 site.
Detailed Summary
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
CountriesUnited States
Collaborators--
Timeline
N/ARecruiting
201320142015201620172018201920202021202220232024202520262027202820292030203120322033
Enrollment StartSep 2012
First PostedJun 2013
TodayJul 2026
Primary CompletionJul 2032
First PostedJun 21, 2013
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2032
TodayJul 2, 2026
Enrollment to primary: 19.8 yearsPosted 13.0 years agoPrimary completion in 6.0 years